Antitrust-Related Recent Developments: FTC/DOJ Aggressive Merger Enforcement Continues

Sep 21, 2016

Reading Time : 1 min

The DOJ has also filed actions seeking to block two significant mergers in the health insurance industry, namely Anthem’s bid to acquire Cigna and Aetna’s bid to acquire Humana. Although the DOJ frames the mergers as five national companies merging into three, the complaints – filed together on July 21, 2016 – focus on different alleged relevant antitrust markets. The Aetna complaint highlights reduced competition between the companies providing Medicare Advantage coverage. For Anthem, the DOJ alleges that the merger is likely to cause harm to: (1) large group employers in 35 metropolitan areas; (2) national account customers for commercial insurance; and (3) healthcare providers in the same 35 metropolitan areas. Both Aetna and Anthem appear committed to litigating; we expect Aetna to be decided in December and Anthem in early January.

Both the FTC and the DOJ are closely reviewing mergers in other industries. The FTC is in the midst of examining Walgreens’ $17.2 billion acquisition of Rite Aid announced on October 27, 2015, and ChemChina’s $43 billion cash deal for Syngenta announced on February 3, 2016. The DOJ is looking into the $68.6 billion merger between Dow Chemical and DuPont announced on December 11, 2015. We anticipate the DOJ to also closely investigate the recently announced $66 billion takeover of Monsanto Company by Bayer AG. 

Share This Insight

Previous Entries

Deal Diary

April 12, 2023

Read More

Deal Diary

2022-12-15

On December 14, 2022, the Securities and Exchange Commission (SEC) adopted amendments regarding Rule 10b5-1 insider trading plans and related disclosures. The amendments aim to strengthen investor protections concerning insider trading and to help shareholders understand when and how insiders are trading in securities for which they may at times have material nonpublic information (MNPI). In light of these amendments, issuers should review and revise, if needed, their insider trading policies and equity grant policies.

Read more.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.